Current Pipeline

INO-3107 is a DNA immunotherapy candidate designed to enable the body to mount an effective immune response to HPV 6 and 11, the strains of HPV that cause RRP, a rare disease of the respiratory tract.

VGX-3100 is a DNA immunotherapy candidate designed to enable the body to mount an effective immune response to HPV 16 and 18, the strains of HPV that cause anal dysplasia and cancer.

INO-3112 is a DNA immunotherapy candidate targeting HPV 16 and 18, the strains of HPV that cause most HPV+ throat cancer. LOQTORZI^® is an FDA-approved anti-PD-1 checkpoint inhibitor from Coherus Oncology.

VGX-3100 is a DNA immunotherapy candidate designed to enable the body to mount an effective immune response to HPV 16 and 18, the strains of HPV that cause cervical dysplasia (HSIL) and cancer. (INOVIO product rights: ex-China)

INO-5401 is a cancer immunotherapy candidate designed to drive immune responses against the hTERT, WT1, and PSMA tumor associated antigens. LIBTAYO^® is an FDA approved PD-1 checkpoint inhibitor from Regeneron. This combination therapy includes INO-9012, a T cell immune activator. Glioblastoma is one of the most complex, deadly, and treatment-resistant brain cancers.

INO-5412 is a cancer immunotherapy candidate composed of INO-5401 and T cell immune activator INO-9012 in a single vial. Cadonilimab is Akeso’s first-in-class PD-1/CTLA-4 bispecific antibody checkpoint inhibitor. Glioblastoma is one of the most complex, deadly, and treatment-resistant brain cancers.

INO-5401 is a cancer immunotherapy candidate designed to drive immune responses against the hTERT, WT1, and PSMA tumor associated antigens. Researchers are investigating if it can generate an immune response to recognize and target the earliest signs of BRCA-related cancers.

INO-4201 is a DNA medicine candidate in development as a booster to the preventative vaccine ERVEBO^®, which protects against the Ebola Zaire virus.

INO-6160 is in development as a prophylactic DNA medicine against HIV. It is composed of one plasmid encoding for an HIV trimer antigen and one encoding for the human IL-12 cytokine as an immune stimulant.

INO-6172 is INOVIO’s first DNA-Launched Nanoparticle (DLNP) candidate to enter clinical trials. This trial is evaluating the safety and immunogenicity of INO-6172 as a prophylactic DNA medicine in adults without HIV.

This trial provides the first clinical proof-of-concept that DNA-Encoded Monoclonal Antibodies (DMAbs^™) can be durably and tolerably expressed in humans.

INOVIO is advancing research with DNA-Encoded Monoclonal Antibody (DMAb^™) technology in multiple targets that could benefit from in vivo-generated monoclonal antibody therapy.

INOVIO is advancing research with DNA-encoded Protein (DPROT) technology in Hemophilia A, a rare genetic disease in which patients lack sufficient Factor VIII protein for blood clotting.

INOVIO is advancing research with DNA-encoded Protein (DPROT) technology in Hypophosphatasia, a rare genetic disease caused by a deficiency in the alkaline phosphatase (ALP) enzyme.

INOVIO is advancing research with DNA-encoded Protein (DPROT) technology for Fabry Disease, a rare genetic disease caused by a deficiency of the enzyme alpha-galactosidase A.